Rti surgical, inc.And tutogen medical (b)(6) a wholly owned subsidiary of rti, received a complaint of post-operative graft at the nasal dorsum following an open rhinoplasty procedure performed on (b)(6) 2014.On (b)(6) 2014, the pt returned for f/u without complications noted.Approx 2 days later, the pt developed redness over the nose and into the weekend developed facial swelling (eyes and jowls) with no fever or symptoms of infection noted.The pt was prescribed steroids and antibiotic therapy.On (b)(6) 2014, the pt underwent a revision procedure.
|
Investigation: the graft was sent for histopathological review.Mfg records re-review was also conducted.Investigation results: results of histopathologic review consistent with a chronic inflammatory response and hypersensitivity reaction.No deviations were noted during the mfg records re-review for lot# nz12390137.The graft underwent a validated sterilization method: tutoplast which includes gama irradiation after packaging.To date, rti has distributed 43 grafts from the lot without related complaints.According to the mfg records, label id 000000012738053 was manufactured to spec prior to distribution.Conclusion: although implant therapy is highly successful and predictable, it is not without possible early and/or late complications.Communication with the physician documented the pt had an allergic reaction to the graft with no evidence of infection noted.
|